Pin1 inhibitors such as all-trans retinoic acid (ATRA) and KPT-6566 showed a dampening of Pin1-dependent oncogenic phenotypes and growth in vivo, as well as curbed self-renewal capabilities of breast cancer stem cells. This evidence concerns the gene PIN1 and breast carcinoma.